Abstract:Activity-based drug screens have successfully led to the development of various inhibitors of the catalytic activity of aurora kinases (AURKs), major regulatory kinases of cell division. Disrupting the localization of AURKB, rather than its catalytic activity, represents a largely unexplored alternative approach to disabling AURKB-dependent processes. Localization disruptors could be just as specific as direct inhibitors of AURKB activity, may bypass their off-target and select on-target toxicities, and are likely less susceptible to drug resistance resulting from mutations of the AURKB catalytic site. In this study, we demonstrate that the pan-AURK inhibitor AMG900 works at a low concentration not by inhibiting the phosphorylation of H3 at Ser10, an AURKB substrate, but by disrupting the mitotic localization of AURKB. Structural deletion studies pinpoint this undescribed activity to the 2-phenoxy-3,4′-bipyridine moiety of AMG900. Guided by a mechanism-informed phenotypic screening (MIPS) assay, the drug fragment is optimized into a novel class of inhibitors that, at low nanomolar concentrations, can disable AURKB through disruption of its mitotic localization and have desirable oral PK properties. Hierarchical clustering of cell fitness profiles reveals that these compounds cluster with each other, rather than with known AURK inhibitors such as AMG900 and VX-680. Validation studies in mice demonstrate that compound 15a elicits mitotic arrest and apoptosis in NCI–H23 human lung adenocarcinoma xenografts, resulting in a pronounced suppression of tumor growth. The discovery and optimization of compounds that disrupt AURKB localization are successfully facilitated by MIPS. Our findings suggest that 2-phenoxy-3, 4′-bipyridine derivatives have the potential to be further developed as effective therapeutics for the treatment of malignancy by delocalizing AURKB.

Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors

Discovery of Novel 2,4-Disubstituted Pyrimidines As Aurora Kinase Inhibitors.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Discovery of new pyrazole-4-carboxamide analogues as potential anticancer agents targeting dual Aurora kinase A and B

Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen

Discovery of Inhibitors of Aurora/PLK Targets As Anticancer Agents.

Synthesis and Biological Evaluation of 2,4-Diaminopyrimidines As Selective Aurora A Kinase Inhibitors.

Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.

Discovery of 4-Aminoquinazoline—urea Derivatives As Aurora Kinase Inhibitors with Antiproliferative Activity

Synthesis and Biological Evaluation of Aurora Kinases Inhibitors Based on N-trisubstituted Pyrimidine Scaffold

Design, Synthesis and Bioevaluation of N-trisubstituted Pyrimidine Derivatives As Potent Aurora A Kinase Inhibitors

Design, Synthesis, Biological Evaluation of 6-(2-amino-1h-benzo[d]imidazole-6-yl)quinazolin-4(3h)-one Derivatives As Novel Anticancer Agents with Aurora Kinase Inhibition.

Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins

Synthesis and Biological Evaluation of 2,4-Disubstituted Phthalazinones As Aurora Kinase Inhibitors.

Structure-based Drug Design: Synthesis and Biological Evaluation of Quinazolin-4-amine Derivatives As Selective Aurora A Kinase Inhibitors.

2-Phenoxy-3, 4′-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization

Design, Synthesis and Bioevaluation of Dihydropyrazolo[3,4-B]pyridine and Benzo[4,5]imidazo[1,2-A]pyrimidine Compounds As Dual KSP and Aurora-A Kinase Inhibitors for Anti-Cancer Agents.

Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1

Pharmacophore Modelling and Virtual Screening for Identification of New Aurora-A Kinase Inhibitors